January 22, 2025 - 02:37
After facing a regulatory setback in 2022, Sanofi’s consumer healthcare division, Opella, has received approval from the FDA to advance its efforts to transition its erectile dysfunction medication, Cialis, from prescription to over-the-counter (OTC) status. This marks a significant milestone for the company, which had previously encountered challenges due to concerns over the study's protocol design.
The FDA's initial hold on the prescription-to-OTC study raised questions about the methodology and safety measures proposed by Opella. Following a thorough review and subsequent modifications to the study design, the agency has now granted the green light, allowing the company to proceed with its research.
The move to make Cialis available OTC could potentially enhance accessibility for individuals seeking treatment for erectile dysfunction, reflecting a growing trend in the healthcare industry to simplify access to medications. As Opella embarks on this new phase, the outcomes of the study will be closely monitored by both healthcare professionals and consumers alike.
